ACM
ENTA icon

ADAR1 Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

ADAR1 Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6M Buy
1,344,510
+1,293,153
+2,518% +$17.4M 0.9% 25
2026
Q1 		$649K Buy
51,357
+10,000
+24% +$134K 0.04% 188
2025
Q4 		$652K Buy
+41,357
New +$525K 0.05% 172

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's ENTA Position: Q2 2026 in Review

ADAR1 Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 2,518% in Q2 2026, buying an estimated $17.4M and bringing the position to 1,344,510 shares worth $19.6M. The position accounts for 0.9% of the portfolio, ranked #25.

ADAR1 Capital Management first reported a position in ENTA in Q4 2025 and has held it in 3 quarters since. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • ADAR1 Capital Management held 1,344,510 shares of Enanta Pharmaceuticals worth $19.6M as of Q2 2026.
  • ADAR1 Capital Management bought 1,293,153 Enanta Pharmaceuticals shares in Q2 2026, an estimated $17.4M.
  • Enanta Pharmaceuticals made up 0.9% of ADAR1 Capital Management's portfolio in Q2 2026, its #25 holding.
  • ADAR1 Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.